Lancashire and South Cumbria
Formulary
4 Central nervous system
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents:
mlcsu.lscformulary@nhs.net
.
For more information about the formulary development process, please see:
https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
04-06 Other drugs for Ménière's disease
Betahistine Dihydrochloride
Formulary
Tablets 8mg, 16mg
Links
Hypersalivation – can hyoscine hydrobromide be used to treat it?
Hypersalivation treatment options
MHRA Drug Safety Update April 2016: Apomorphine with domperidone: minimising risk of cardiac side effects
MHRA Drug Safety Update Dec 2019: Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents
MHRA Dug Safety Update Jan 2020: Ondansetron in pregnancy – small increased risk of oral clefts following use in the first 12 weeks of pregnancy
MHRA update on restricted dose information (Aug 13)
MHRA: Advice for domperidone (April 2014)
MHRA: Domperidone: risks of cardiac side effects
MHRA: Metoclopramide: risk of neurological adverse effects
MHRA: Ondansetron: small increased risk of oral clefts following use in the first 12 weeks of pregnancy
NICE CG150: Headaches in over 12s: diagnosis and management
NICE CG84: Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management
NICE TA:919 Rimegepant for treating migraine
NICE TA906: Rimegepant for preventing migraine
NICE TA919: Rimegepant for treating migraine
NICE TA973: Atogepant for preventing migraine
NICE: Management of vomiting in children and young people with gastroenteritis: ondansetron
Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
UKMI: Domperidone - New restrictions in GI conditions (May 2014)
Key
Full Site